CORBF vs. FLGT, LFMD, CSTL, PSNL, INNV, CELC, FTRE, SBC, OMDA, and AUNA
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Fulgent Genetics (FLGT), LifeMD (LFMD), Castle Biosciences (CSTL), Personalis (PSNL), InnovAge (INNV), Celcuity (CELC), Fortrea (FTRE), SBC Medical Group (SBC), Omada Health (OMDA), and Auna (AUNA). These companies are all part of the "healthcare" industry.
Global Cord Blood vs. Its Competitors
Global Cord Blood (NYSE:CORBF) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.
Global Cord Blood has a net margin of 0.00% compared to Fulgent Genetics' net margin of -13.94%. Global Cord Blood's return on equity of 0.00% beat Fulgent Genetics' return on equity.
Global Cord Blood has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Fulgent Genetics has a consensus target price of $24.00, indicating a potential upside of 19.64%. Given Fulgent Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Global Cord Blood.
48.1% of Fulgent Genetics shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Global Cord Blood has higher earnings, but lower revenue than Fulgent Genetics.
In the previous week, Global Cord Blood and Global Cord Blood both had 2 articles in the media. Global Cord Blood's average media sentiment score of 0.00 equaled Fulgent Genetics'average media sentiment score.
Summary
Fulgent Genetics beats Global Cord Blood on 8 of the 12 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CORBF) was last updated on 7/6/2025 by MarketBeat.com Staff
Free CORBF Stock Alerts